Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 13/20 | 0.45 |
| ▸ | OXTR | P30559 | 11/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133697 | 0.84 | OXTR (0.53) | AVPR1AOXTRAVPR2AVPR1BTACR1 | |
| SCHEMBL4121273 | 0.79 | OXTR (0.70) | AVPR1AOXTRAVPR2AVPR1BTACR1 | |
| SCHEMBL14981470 | 0.74 | AVPR1A (0.37) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL4124995 | 0.69 | OXTR (0.53) | AVPR1AOXTRAVPR2AVPR1BTACR1 | |
| SCHEMBL4121502 | 0.61 | OXTR (0.80) | AVPR1AOXTRAVPR2AVPR1BTACR1 | |
| SCHEMBL17339953 | 0.61 | CARM1 (0.64) | SIGMAR1DRD4TACR1CARM1PRMT6 | |
| SCHEMBL4119793 | 0.60 | OXTR (0.81) | AVPR1AOXTRAVPR2AVPR1BTACR1 | |
| SCHEMBL23373195 | 0.60 | CARM1 (0.70) | SIGMAR1DRD4TACR1CARM1PRMT6 | |
| SCHEMBL18616222 | 0.60 | CARM1 (0.59) | SIGMAR1DRD4TACR1CARM1PRMT6 | |
| SCHEMBL3126964 | 0.60 | CARM1 (0.55) | SIGMAR1DRD4TACR1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | AVPR1A 6/4885OXTR 1/4885AVPR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.